BCM
VRCA icon

Bridgeway Capital Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Bridgeway Capital Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,000
Closed -$99.7K – 1315
2025
Q4 		$99.7K Hold
12,000
– – ﹤0.01% 1124
2025
Q3 		$51.7K Buy
+12,000
New +$72.4K ﹤0.01% 1166
2025
Q2 		– Sell
-5,000
Closed -$22.1K – 1274
2025
Q1 		$22.1K Sell
5,000
-260
-5% -$1.68K ﹤0.01% 1154
2024
Q4 		$36.8K Sell
5,260
-460
-8% -$5.06K ﹤0.01% 1166
2024
Q3 		$82.9K Sell
5,720
-2,500
-30% -$113K ﹤0.01% 1176
2024
Q2 		$599K Hold
8,220
– – 0.01% 822
2024
Q1 		$487K Sell
8,220
-2,455
-23% -$136K 0.01% 940
2023
Q4 		$781K Buy
10,675
+3,220
+43% +$132K 0.02% 823
2023
Q3 		$290K Hold
7,455
– – 0.01% 1017
2023
Q2 		$430K Hold
7,455
– – 0.01% 947
2023
Q1 		$485K Hold
7,455
– – 0.01% 895
2022
Q4 		$205K Buy
7,455
+5,000
+204% +$133K 0.01% 1082
2022
Q3 		$72K Hold
2,455
– – ﹤0.01% 1322
2022
Q2 		$47K Hold
2,455
– – ﹤0.01% 1285
2022
Q1 		$199K Buy
+2,455
New +$202K ﹤0.01% 1171

Other funds holding VRCA

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgeway Capital Management's VRCA Position: Q1 2026 in Review

Bridgeway Capital Management sold out of Verrica Pharmaceuticals (VRCA) in Q1 2026, closing a stake of 12,000 shares — an estimated $99.7K sold.

Bridgeway Capital Management first reported a position in VRCA in Q1 2022 and held it in 15 quarters. The position peaked at $781K in Q4 2023. 39 funds tracked by Wall St. Rank hold VRCA as of Q1 2026.

  • Bridgeway Capital Management reported no remaining Verrica Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bridgeway Capital Management sold 12,000 Verrica Pharmaceuticals shares in Q1 2026, an estimated $99.7K.
  • Bridgeway Capital Management first reported a position in Verrica Pharmaceuticals in Q1 2022 and held it in 15 quarters.
  • Bridgeway Capital Management's Verrica Pharmaceuticals position peaked at $781K in Q4 2023.
  • 39 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.